Diabetes
Refine Search
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
The BRIC diabetes drugs market in the group of BRIC countries (Brazil, Russian, India and China) is expected to grow from $3.9 billion in 2009 to reach $8.7 billion by 2014, growing at a compound annual growth rate (CAGR) of 17.1% from 2009 to 2014, notes a new report added to the offering of Research and Markets. Oral drugs accounted for around 65% of the market in 2009, but injectables are expected to have a higher CAGR of 21.9%. 21 April 2010
Biotechnology
It was a good news day last Friday for Japan's biggest drugmaker, Takeda Pharmaceutical, which announced that New Drug Applications for five new products were approved by the Japanese Ministry of Health, Labor and Welfare, and that US biotechnology major Amgen had posted strong Phase III trial results for one of the compounds, Vectibix (panitumumab). 19 April 2010
Pharmaceutical
US drugmaker Strativa Pharmaceuticals says that the Food and Drug Administration has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis (OPC), or thrush, in adults and children age 16 and older. Oravig is the first and only local, oral prescription formulation of miconazole - an antifungal medication - approved for this use in the USA. 19 April 2010
Pharmaceutical
French ophthalmology pharmaceuticals company Novagali is in talks with several groups, including fellow France-based drug major Sanofi-Aventis SA, and is also considering a possible initial public offering, according to the local newspaper Les Echos, which cited the eye firm's chairman, Jerome Martinez, as its source. 15 April 2010
Pharmaceutical
Swiss drug major Roche has agreed with Israel's Elron Electronics to acquire 100% of its majority-owned subsidiary Medingo, which is engaged in the development of a semi-disposable insulin patch pump. Under the terms of the agreement, Roche will pay Medingo's shareholders an upfront payment of $160 million as well as up to 25% of the upfront payment in performance related milestones. 15 April 2010
Pharmaceutical
US drug developer CPEX Pharmaceuticals has been strongly criticized by one of its shareholders for mis-applying $17 million in failed R&D over its Nasulin (nasal insulin spray) program after a failed Phase IIa clinical trial, and refusing a fully-financed tender offer. The firm said it will now seek to sell or out-license the program. 14 April 2010
Pharmaceutical
Clinical data on intravenous dosing and a once-weekly version of drug major Eli Lilly and Amylin's type 2 diabetes therapy Byetta (exenatide) - which already generates turnover of nearly $700 million a year in its current indications - 'seem to give a similar signal' as cancers seen in rodent studies of Danish drugmaker Novo Nordisk competitor drug Victoza (liraglutide), according to Curtis Rosebraugh, head of the US Food and Drug Administration's Office of Drug Evaluation II, in a January 25 memo that was posted on the agency's web site last Friday and reported by the Bloomberg news service. 12 April 2010
Pharmaceutical
French drug major Sanofi-Aventis has entered into a licensing deal with USA-based CureDM on a novel human peptide, Pancreate, which could restore a patients' ability to produce insulin and other pancreatic hormones in both type 1 and type 2 diabetes. 8 April 2010
Biotechnology
French drug major Sanofi-Aventis had a couple of busy news days, entering a pay-to-delay generics deal in the USA, announcing new investments and signing deal for better monitoring of its leading insulin products for diabetic patients. 1 April 2010
Generics
European Medicines Agency (EMEA) yesterday afternoon recommended a precautionary recall of batches of clopidogrel-containing medicines from Acino Pharma GmbH and has revealed that an application for a copy version of a diabetes drug has been withdrawn. 26 March 2010
Pharmaceutical
The majority of researchers who have published articles supporting UK drug giant GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) after it was linked to heart disease in 2007 had financial ties to the company, according to a Mayo Clinic report reported in the British Medical Journal. 22 March 2010
Pharmaceutical
Turkey's new procedure regarding new-generation diabetes medications introduced in the draft Health-Care Implementation Notification (SUT) 2010, announced by the Social Security Institution (SGK), has sparked reaction from patients and health care professionals. The Notification restricts prescribing authority of new-generation diabetes medications to endocrinologists, preventing internists from prescribing these medicines. 18 March 2010
Pharmaceutical
11beta-HSD1 inhibitors appear to be attractive R&D products for the treatment of type 2 diabetes, because a large number of major biotechnology and pharmaceutical companies are involved in their development, and this pipeline, although very young, already has 70% of products in clinical stage of development., according to a new report, titled Diabetes R&D Pipeline: 11beta-HSD1 inhibitors, added to the offering of Research and Markets. 18 March 2010
Pharmaceutical
US drugmaker OSI Pharmaceuticals has formally rejected a $3.5-billion takeover bid from Japanese drug major Astellas, telling shareholders yesterday that the offer was too low and it is seeking alternatives in the form of a 'white knight' rescue. 16 March 2010
Pharmaceutical
The US Food and Drug Administration has issued a complete response letter regarding the New Drug Application for Bydureon, an extended-release injectable suspension versions of drug major Eli Lilly and biotech firm Amylin's diabetes drug Byetta (exenatide), which currently generates sales around $700 million a year. Such a letter was also received by MannKind for its insulin-based product Afrezza. 16 March 2010
Pharmaceutical
Jorge Puente, Regional President of WW Pfizer gives MeetTheBoss.tv an inside look into how Pfizer became global. 16 March 2010
Pharmaceutical
There were some disappointments for two leading pharmaceutical companies yesterday, when data were presented at the American College of Cardiology annual meeting, held in Atlanta, which showed that potentially new strategies to prevent and treat diabetes and heart disease failed to improve therapy. 15 March 2010
Biotechnology
Ipsen grants Rhythm exclusive global rights to two metabolic disorder programs for up to $80 million
Paris, France-based biotechnology firm Ipsen has concluded an agreement with US biotech Rhythm Pharmaceuticals for its proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders, granting the latter an exclusive worldwide license for research, development, and commercialization of its melanocortin and ghrelin programs originating from Ipsen research. 15 March 2010
Generics
In what is another deal that is designed to delay the entry of a copy drug on to the US market, Watson Pharmaceuticals says that it has reached a settlement agreement with Japan's largest drugmaker Takeda, and its US subsidiary Takeda Pharmaceuticals North America, resolving outstanding patent litigation related to Watson's generic equivalent version of the type 2 diabetes drug Actos (pioglitazone) 15mg, 30mg and 45mg tablets. 11 March 2010
Pharmaceutical
Rising obesity levels across the western world could result in a near doubling of the type 2 diabetes drug market by 2018, according to Datamonitor. The independent business analyst forecasts that the antidiabetics market will be worth $37 billion by 2018 up from $20 billion in 2008. 11 March 2010
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze